HomeComparePOLBF vs GBDC

POLBF vs GBDC: Dividend Comparison 2026

POLBF yields 3344.48% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 POLBF wins by $1284463355836.25M in total portfolio value
10 years
POLBF
POLBF
● Live price
3344.48%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1284463355857.10M
Annual income
$1,213,110,815,498,324,000.00
Full POLBF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — POLBF vs GBDC

📍 POLBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPOLBFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, POLBF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
POLBF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

POLBF
Annual income on $10K today (after 15% tax)
$284,280.94/yr
After 10yr DRIP, annual income (after tax)
$1,031,144,193,173,575,300.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, POLBF beats the other by $1,031,144,193,159,592,200.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of POLBF + GBDC for your $10,000?

POLBF: 50%GBDC: 50%
100% GBDC50/50100% POLBF
Portfolio after 10yr
$642231677938.98M
Annual income
$606,555,407,757,387,400.00/yr
Blended yield
94.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

POLBF
No analyst data
Altman Z
39.8
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

POLBF buys
0
GBDC buys
0
No recent congressional trades found for POLBF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPOLBFGBDC
Forward yield3344.48%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$1284463355857.10M$20.85M
Annual income after 10y$1,213,110,815,498,324,000.00$16,450,733.83
Total dividends collected$1279557275592.29M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: POLBF vs GBDC ($10,000, DRIP)

YearPOLBF PortfolioPOLBF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$345,148$334,448.16$12,492$1,791.70+$332.7KPOLBF
2$11,157,548$10,788,239.94$16,527$3,160.58+$11.14MPOLBF
3$337,872,856$325,934,279.31$23,588$5,904.90+$337.85MPOLBF
4$9,585,767,941$9,224,243,985.35$37,141$11,901.65+$9585.73MPOLBF
5$254,836,586,625$244,579,814,927.95$66,205$26,463.38+$254836.52MPOLBF
6$6,349,429,806,239$6,076,754,658,549.98$137,452$66,612.65+$6349429.67MPOLBF
7$148,295,333,941,378$141,501,444,048,701.88$342,372$195,298.53+$148295333.60MPOLBF
8$3,247,334,232,557,481$3,088,658,225,240,206.50$1,053,292$686,954.33+$3247334231.50MPOLBF
9$66,684,617,157,738,690$63,209,969,528,902,180.00$4,111,439$2,984,416.95+$66684617153.63MPOLBF
10$1,284,463,355,857,104,100$1,213,110,815,498,324,000.00$20,849,974$16,450,733.83+$1284463355836.25MPOLBF

POLBF vs GBDC: Complete Analysis 2026

POLBFStock

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Full POLBF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this POLBF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

POLBF vs SCHDPOLBF vs JEPIPOLBF vs OPOLBF vs KOPOLBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.